English version Ukrainian version
Last issue Archive Editorial board Instructions to authors Contact us




This site supported by
 


Ukr. Bioorg. Acta 2021, Vol. 16, N1, 18-24.

Synthesis of novel pyrazoline-thiazolidin-4-one hybrids and evaluation their biological activity

Serhii M. Holota1,2*

1Danylo Halytsky Lviv National Medical University, 69 Pekarska St., Lviv, 79010, Ukraine
2Lesya Ukrainka Volyn National University, 13 Voli Ave., Lutsk, 43025, Ukraine

tel.: +380-97-226-0066; e-mail: golota_serg@yahoo.com

ABSTRACT
In the present work, the synthesis of pyrazoline-thiazolidin-4-one hybrids and their pharmacological properties are described. The structure of compounds is characterized using
1H, 13C NMR, and LC-MS spectra. The antioxidant (DPPH assay), antimicrobial (Gram-positive bacterium Lactobacillus plantarum, Gram-negative bacterium Escherichia coli, and yeasts Candida albicans, MIC determination), redox (cyclic voltammetry) as well as herbicidal activity (against grass species Agrostis stolonifera) of compounds have been studied. All derivatives have demonstrated radical scavenging activity with IC50 values in the range from 4.67-7.12 mM in the DPPH test. The tested compounds presented very low antimicrobial and herbicidal activity and no redox peaks were observed in the cyclic voltammetry studies.

KEYWORDS
pyrazoline-thiazolidin-4-ones hybrids; DPPH assay; antimicrobial/herbicidal activity; cyclic voltammetry.

Full text:(PDF, in English)

REFERENCES
1. Sies, H.; Jones, D. P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell. Biol. 2020, 21, 363-383.
2. Zarkovic, N. Roles and Functions of ROS and RNS in Cellular Physiology and Pathology. Cells 2020, 9, 767.
3. Sova, M.; Saso, L. Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review. Drug. Des. Devel. Ther. 2018, 12, 3181-3197.
4. Freitas, R. H. C. N.; Fraga, C. A. M. NF-kB-IKK? Pathway as a Target for Drug Development: Realities, Challenges and Perspectives. Curr. Drug. Targets. 2018, 19, 1933-1942.
5. Ottana, R.; Maccari, R.; Giglio, M.; Del Corso; A., Cappiello; M., Mura, U.; Cosconati, S.; Marinelli, L.; Novellino, E.; Sartini, S. et al. Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. Eur. J. Med. Chem. 2011, 46, 2797-806.
6. Kumar, V.; Sharma, A.; Sharma, P. C. Synthesis of some novel 2,5-disubstituted thiazolidinones from a long chain fatty acid as possible anti-inflammatory, analgesic and hydrogen peroxide scavenging agents. J. Enzyme Inhib. Med. Chem. 2011, 26, 198-203.
7. Raut, D. G.; Lawand, A. S.; Kadu, V. D.; Hublikar, M. G.; Patil, S. B.; Bhosale, D. G.; Bhosale, R. B. Synthesis of Asymmetric Thiazolyl Pyrazolines as a Potential Antioxidant and Anti-Inflammatory Agents. Polycycl. Arom. Comp. 2020, 1-10.
8. Upadhyay, N.; Tilekar, K.; Loiodice, F.; Anisimova, N. Y.; Spirina, T. S.; Sokolova, D. V.; Smirnova, G. B.; Choe, J. Y.; Meyer-Almes, F. J.; Pokrovsky, V. S.; Lavecchia, A.; Ramaa, C. S. Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. Bioorg. Chem. 2020, 107, 104527.
9. Borcherding, D. C.; Siefert, M. E., Lin, S., Brewington, J., Sadek, H., Clancy, J. P., Plafker, S. M., Ziady, A. G. Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. J. Clin. Invest. 2019, 129, 3448-3463.
10. Robledinos-Anton, N.; Fernandez-Gines, R.; Manda, G.; Cuadrado, A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid. Med. Cell. Longev. 2019, 2019, 9372182.
11. Lu, M.; Zhang, X., Zhao, J.; You, Q.; Jiang, Z. A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions. Redox Biol. 2020, 34, 101565.
12. Derkach, G. O.; Golota, S. M.; Trufin, Y. O.; Roman, O. M.; Sementsiv, G. M.; Demchuk, I. L.; Soronovych, I. I.; Kutsyk, R. V.; Grellier, P.; Lesyk, R. B. Synthesis and biological activity of 5-aminomethylene-2-thioxotiazolidin-4-ones derivatives. Pharm. Rev. 2017, 2, 5-11 (In Ukrainian).
13. Derkach, G. .; Golota, S. .; Zasidko, V. V.; Soronovych, I. .; Kutsyk, R. V.; Lesyk, R. B. The synthesis and the study of antimicrobial properties of 5-r,r-aminometylene derivatives of thiazolidine-2, 4-dione and 4-thioxothiazolidine-2-one. J. Org.Pharm. Chem. 2016, 14, 32-37.
14. Holota, S. M.; Derkach, G. O.; Zasidko, V. V.; Trokhymchuk, V. V.; Furdychko, L. O.; Demchuk, I. L.; Semenciv, G. M.; Soronovych, I. I.; Kutsyk, R. V.; Lesyk, R. B. Features of antimicrobial activity of some 5-aminomethylene-2-thioxo-4-thiazolidinones. Biopolym. Cell. 2019, 35, 371-380.
15. Holota, S.; Kryshchyshyn, A.; Derkach, H.; Trufin, Y.; Demchuk, I.; Gzella, A.; Grellier, P.; Lesyk, R. Synthesis of 5-enamine-4-thiazolidinone derivatives with trypanocidal and anticancer activity. Bioorg Chem. 2019, 86, 126-136.
16. Holota, S.M.; Derkach, H. O.; Demchuk, I. L.; Vynnytska, R. B.; Antoniv, O. I.; Furdychko, L. O.; Nektegayev, I.O.; Lesyk, R. B. Synthesis and in vivo evaluation of pyrazoline-thiazolidin-4-one hybrid Les-5581 as a potential non-steroidal anti-inflammatory agent. Biopolym.Cell., 2019, 35, 437-447.
17. Ajantha, J.; Varathan, E.; Bharti, V.; Subramanian, V.; Easwaramoorthi, S.; Chand, S. Photophysical and charge transport properties of pyrazolines. RSC Adv. 2016, 6, 786-795.
18. Radi, M.; Botta, L.; Casaluce, G.; Bernardini, M.; Botta, M. Practical One-Pot Two-Step Protocol for the Microwave-Assisted Synthesis of Highly Functionalized Rhodanine Derivatives. J. Comb. Chem. 2010, 12, 200-205.
19. Chebanov, V. A.; Desenko, S. M.; Gurley, T. W. Azaheterocycles based on a,?-unsaturated carbonyls, Springer-Verlag Berlin Heidelberg, 2008.
20. Brand-Williams, W.; Cuvelier, M.; Berset, C. Use of a free radical method to evaluate antioxidant activity. LWT Food Science and Technology, 1995, 28, 25-30.
21. Humphries, R.M.; Ambler, J.; Mitchell, S.L.; Castanheira, M.; Dingle, T.; Hindler, J.A.; Koeth, L.; Sei, K. CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J. Clin. Microbiol. 2018, 56, e01934-1917.

22. Nenoff, P.; Oswald, U.; Haustein, U.F. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test. Mycoses, 1999, 42, 629-639.

Full-text in PDF  

 

Home